Imagine a brain stroke like a blocked pipe that stops water from reaching a garden. This drug acts like a specialized tool that keeps the pipes open, ensuring oxygen and nutrients keep flowing. By preventing the vessels from clamping shut, it stops brain cells from dying and reduces long-term disability.
Subarachnoid hemorrhage has a 50% short-term mortality rate and causes severe long-term disability. Current drug therapies have little to no effect, leaving a massive unmet medical need.
A lead drug candidate, EDV2209, and the successful execution of early-phase human clinical trials (Phase I/II).
If you are a drug development firm dealing with the lack of effective stroke treatments — this project developed EDV2209 that reduces the tightening of blood vessels in the brain. This provides a new pharmacological path for treating subarachnoid hemorrhage.
If you are a hospital dealing with a 50% short-term mortality rate for SAH patients — this project developed a clinical validation process for EDV2209 that aims to keep brain vessels open. This could significantly reduce the number of survivors with life-long cognitive impairment.
If you are an investor dealing with the high socioeconomic burden of stroke — this project developed a first-in-man phase I/II trial for an orphan drug. It targets a condition that accounts for 25% of all productive life-years lost to stroke.
Based on available project data, the specific price per dose or treatment cost is not disclosed; only the EU contribution of EUR 2,500,000 for development is mentioned.
The project has produced the first batch of investigational medicinal product (IMP), but based on available project data, it is currently in the clinical trial phase rather than full industrial scale.
Based on available project data, the drug EDV2209 is developed by Edvince Aktiebolag, but specific licensing terms or patent numbers are not listed.
The project received approvals from the Danish Medicines Agency (DKMA) and Ethics Committee for first-in-man phase I/II clinical trials.
The project period ran from 2022-01-01 to 2024-10-31, with patient enrollment starting in March 2022.
The project is led by a single Swedish SME, Edvince Aktiebolag, representing 100% of the consortium. This lean structure indicates a high level of control over the IP and a direct path from research to clinical application, though it lacks the diverse industrial partnerships typically seen in larger consortia.
Contact Edvince Aktiebolag in Sweden regarding EDV2209 clinical data.
Contact SciTransfer for a detailed analysis of the phase I/II trial results.
